Literature DB >> 16174807

Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines.

David Hallifax1, Helen C Rawden, Nancy Hakooz, J Brian Houston.   

Abstract

Predictions of intrinsic clearance (CL(int)) from human liver microsomes often underestimate in vivo observations. In this study, a series of five benzodiazepines was used as prototypic CYP3A4 substrates to investigate the prediction of clearance from the less studied alternative in vitro system, cryopreserved human hepatocytes. Formation of the two major metabolites from midazolam, triazolam, diazepam, flunitrazepam, and alprazolam was measured in cryopreserved human hepatocytes from five donors; the kinetics were characterized and CL(int) values were determined and scaled to predict CL(int) in vivo. At least one of the two major pathways of metabolic clearance of each benzodiazepine was characterized by autoactivation in hepatocytes; the extent to which this occurred varied depending on substrate and liver (up to 8-fold). Heteroactivation by testosterone of these pathways was also observed (up to 6-fold). The maximum autoactivated clearance was used to predict in vivo CL(int) (1.6-138 ml/min/kg) which closely agreed with values previously obtained using human liver microsomes. Comparison with in vivo CL(int) indicates that cryopreserved human hepatocytes systematically underpredict CL(int). When three previous studies (documenting CL(int) for substrates of various enzymes in cryopreserved human hepatocytes using drug depletion-time profiles) were considered as well, the combined data show a consistent underprediction of 5.6-fold. Collectively it is demonstrated that the predicted hepatic intrinsic clearances from cryopreserved hepatocytes show an excellent rank order with in vivo findings but are systematically underpredicting the in vivo value.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16174807     DOI: 10.1124/dmd.105.005389

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

Review 1.  Prediction of hepatic clearance in human from in vitro data for successful drug development.

Authors:  Masato Chiba; Yasuyuki Ishii; Yuichi Sugiyama
Journal:  AAPS J       Date:  2009-04-30       Impact factor: 4.009

2.  Closed form solutions and dominant elimination pathways of simultaneous first-order and Michaelis-Menten kinetics.

Authors:  Xiaotian Wu; Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-02-13       Impact factor: 2.745

3.  Interlaboratory Variability in Human Hepatocyte Intrinsic Clearance Values and Trends with Physicochemical Properties.

Authors:  Christine M Bowman; Leslie Z Benet
Journal:  Pharm Res       Date:  2019-05-31       Impact factor: 4.200

4.  Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells.

Authors:  S Choi; B Sainz; P Corcoran; S Uprichard; H Jeong
Journal:  Xenobiotica       Date:  2009-03       Impact factor: 1.908

5.  Deoxyschizandrin, a naturally occurring lignan, is a specific probe substrate of human cytochrome P450 3A.

Authors:  Jingjing Wu; Yunfeng Cao; Yanyan Zhang; Yong Liu; James Y Hong; Liangliang Zhu; Guangbo Ge; Ling Yang
Journal:  Drug Metab Dispos       Date:  2013-10-16       Impact factor: 3.922

6.  Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data.

Authors:  Jaydeep Yadav; Mehdi El Hassani; Jasleen Sodhi; Volker M Lauschke; Jessica H Hartman; Laura E Russell
Journal:  Drug Metab Rev       Date:  2021-05-25       Impact factor: 6.984

Review 7.  Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development.

Authors:  Yurong Lai; Xiaoyan Chu; Li Di; Wei Gao; Yingying Guo; Xingrong Liu; Chuang Lu; Jialin Mao; Hong Shen; Huaping Tang; Cindy Q Xia; Lei Zhang; Xinxin Ding
Journal:  Acta Pharm Sin B       Date:  2022-03-17       Impact factor: 14.903

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.